FDA ClinicalTrials.gov Report Will Show Growing Rate Of Study Listings
This article was originally published in The Pink Sheet Daily
Executive Summary
The forthcoming report also will show increased disclosure of company sponsors and drug names in trial descriptions. FDA has added language to IND acknowledgement letters to promote compliance with listing requirements.
You may also be interested in...
Acting Head Named For Office Of Women's Health
Theresa Toigo will serve as the acting director of FDA's Office of Women's Health, the agency announced Sept. 16
Acting Head Named For Office Of Women's Health
Theresa Toigo will serve as the acting director of FDA's Office of Women's Health, the agency announced Sept. 16
ClinicalTrials.Gov Participation Is Up From 2002 Rate Of 35%, FDA Report Says
Agency calls participation in ClinicalTrials.gov "mixed," despite recent increase in use.